Table 1 Baseline characteristics of the study population
|  | All (n = 290) | DM (n = 102) | Non-DM (n = 188) | P-value |
|---|---|---|---|---|
General characteristics | Â | Â | Â | Â |
Age (years) | 64.87 ± 9.21 | 66.29 ± 8.49 | 64.24 ± 9.72 | 0.074 |
Male, n (%) | 201 (69.3) | 68 (66.7) | 133 (70.7) | 0.472 |
Cardiovascular risk factors | Â | Â | Â | Â |
BMI (kg/m2) | 25.00 ± 3.07 | 25.59 ± 3.21 | 24.67 ± 2.87 | 0.014 |
Smoking history, n (%) | 68 (23.4) | 22 (21.6) | 46 (24.5) | 0.578 |
Hypertension, n (%) | 203 (70.0) | 75 (73.5) | 128 (68.1) | 0.334 |
Hyperlipidaemia, n (%) | 60 (20.7) | 17 (16.7) | 43 (22.9) | 0.213 |
Atrial fibrillation, n (%) | 15 (5.2) | 6 (5.9) | 9 (4.8) | 0.688 |
PCI performed, n (%) | 229 (79.0) | 86 (84.3) | 143 (76.1) | 0.100 |
LVEF (%) | 62.28 ± 4.84 | 59.48 ± 8.69 | 62.04 ± 5.64 | 0.010 |
CKD, n (%) | 22 (7.6) | 14 (13.7) | 8 (4.3) | 0.004 |
CAD, n (%) | 276 (95.2) | 99 (97.1) | 177 (94.1) | 0.414 |
1- vessel disease | 115 (39.7) | 40 (39.2) | 75 (39.9) | 0.910 |
2- vessel disease | 100 (34.5) | 34 (33.3) | 66 (35.1) | 0.762 |
3- vessel disease | 61 (21.0) | 25 (24.5) | 36 (19.1) | 0.285 |
Laboratory findings | Â | Â | Â | Â |
FBG (mmol/L) | 5.90 ± 2.01 | 6.98 ± 2.59 | 5.30 ± 1.02 | < 0.001 |
HbA1c (%) | 6.49 ± 1.27 | 7.40 ± 1.38 | 6.00 ± 0.77 | < 0.001 |
TC (mmol/L) | 3.65 ± 0.98 | 3.61 ± 0.98 | 3.66 ± 0.95 | 0.691 |
LDL-C (mmol/L) | 1.95 ± 0.87 | 1.91 ± 0.81 | 1.97 ± 0.87 | 0.581 |
Cr (umol/L) | 77.40 ± 20.26 | 78.04 ± 22.89 | 77.05 ± 18.72 | 0.709 |
eGFR (mL/min/1.73m2) | 90.76 ± 21.51 | 90.40 ± 23.66 | 90.96 ± 20.30 | 0.833 |
Cardiovascular medical therapy | Â | Â | Â | Â |
Aspirin, n (%) | 260 (89.7) | 94 (92.2) | 166 (88.3) | 0.303 |
P2Y12 receptor antagonist, n (%) | 233 (80.3) | 85 (83.3) | 148 (78.7) | 0.346 |
Statin, n (%) | 278 (95.9) | 95 (93.1) | 183 (97.3) | 0.159 |
ACEI/ARB, n (%) | 159 (54.8) | 62 (60.8) | 97 (51.6) | 0.133 |
Beta blocker, n (%) | 168 (57.9) | 60 (58.8) | 108 (57.4) | 0.821 |
CCB, n (%) | 149 (51.4) | 45 (44.1) | 104 (55.3) | 0.068 |